Key Points
-
Pfizer offers one of the highest yields in healthcare.
-
AbbVie is a Dividend King with solid growth prospects.
-
The better pick depends on your investing priorities.
-
Pfizer (NYSE: PFE) and AbbVie (NYSE: ABBV) rank among the biggest drugmakers in the world. Both pharma stocks have also been favorites for many income investors through the years.
However, Pfizer and AbbVie offer distinctly different attractions for income investors these days. Pfizer’s 5.9% dividend yield is one of the highest in the healthcare sector. AbbVie’s 2.5% yield isn’t as eye-catching, but the company has increased its dividend for an impressive 53 consecutive years. Which of these stocks is the better pick right now?
Missed AI’s “Act 1”? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn’t buy Nvidia in 2005. But according to our analysts, we’re only at the end of “Act 1″—the R&D phase. “Act 2” is the global rollout. Continue »
The case for Pfizer
It’s obvious what Pfizer’s main argument is: the mouthwatering yield. An investor who bought $10,000 of Pfizer stock would receive nearly $600 per year, compared to only around $250 from investing the same amount in AbbVie.
But is Pfizer’s dividend safe? The company’s payout ratio of roughly 246% could alarm some investors. However, that ratio is based on Pfizer’s GAAP earnings, which include some one-time items such as acquisition-related costs that muddy the waters.
A better metric for assessing Pfizer’s dividend safety is its free cash flow payout ratio. That number currently stands at 89%. Granted, Pfizer doesn’t have much wiggle room at this level, but it’s much more reassuring than the GAAP earnings-based payout ratio.
Importantly, Pfizer’s management is adamant that no dividend cuts are forthcoming despite the company facing a patent cliff over the next couple of years. CFO Cecile Guegan said in the company’s third-quarter earnings call, “So through the LOE [loss of exclusivity] period, our operating cash flow, financial assets, and access to capital markets will give us the ability to continue to invest and maintain the dividend.”
The patent cliff will negatively impact Pfizer’s revenue and earnings growth, though. Still, the company thinks that its newer products and late-stage pipeline candidates will help it return to growth later this decade.
The case for AbbVie
What’s the strongest argument for AbbVie? We’ve already mentioned it: the company’s streak of dividend hikes. AbbVie is a member of the Dividend Kings, an elite group of stocks that have increased their dividends for at least 50 consecutive years.
Importantly, AbbVie hasn’t doled out measly dividend increases in the past. Since its spin-off from Abbott Labs (NYSE: ABT) in 2013, the company has increased its dividend by 355% cumulatively. Over the last five years, AbbVie has grown its dividend by nearly 23%.
While Pfizer faces a steep patent cliff, AbbVie has already successfully navigated through a tough one of its own. For years, the company relied heavily on its blockbuster autoimmune disease drug Humira. But when Humira lost U.S. patent exclusivity in 2023, AbbVie barely skipped a beat.
Skyrizi and Rinvoq played a huge role in AbbVie’s resilience. The two autoimmune disease drugs combined raked in $23 billion in the first nine months of 2026. That’s more than Humira generated annually at its peak.
AbbVie is a major player in areas beyond immunology, too. The company’s neuroscience products, particularly migraine therapies Qulipta and Ubrelvy, enjoy strong sales momentum. AbbVie’s cancer therapies Elahere and Epkinly are also rising stars.
Two answers for two investing priorities
So which of these stocks is the better buy now? I think the answer depends on your investing priorities.
Pfizer is the clear choice for income investors who want to maximize cash flow. The big drugmaker’s dividend yield is hard to beat. Don’t count on dividend increases over the next few years, but Pfizer should be able to maintain the payout at current levels.
If you want both income and growth, though, AbbVie gets the nod. The company doesn’t face the headwinds that Pfizer does. It has a strong product lineup and pipeline. And it’s a safe bet that AbbVie’s dividend will continue to grow for years to come.
Should you buy stock in AbbVie right now?
Before you buy stock in AbbVie, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004… if you invested $1,000 at the time of our recommendation, you’d have $338,083!* Or when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $1,021,163!*
Now, it’s worth noting Stock Advisor’s total average return is 830% — a market-crushing outperformance compared to 209% for the S&P 500. Don’t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of November 14, 2026.
Keith Speights has positions in AbbVie and Pfizer. The Motley Fool has positions in and recommends AbbVie, Abbott Laboratories, and Pfizer. The Motley Fool has a disclosure policy.
